Amyloid-β: An antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease

Free Radical Biology and Medicine

Volumn 31, Issue 9, 2001, Pages 1120-1131

  Kontush, Anatol ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Alzheimer's disease; Amyloid ; Antioxidant; Free radicals; Lipoproteins; Oxidation; Transition metals

Indexed keywords

AMYLOID BETA PROTEIN; ANTIOXIDANT; BRAIN PROTEIN; COPPER; METAL ION; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN MITOCHONDRION; CATALYST; CHELATION; DISEASE COURSE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIOXIDANTS; BINDING SITES; HUMANS; LIPOPROTEINS; METALS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 0035500510     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(01)00688-8     Document Type: Article

References (125)

1. Amyloid, the presenilins and Alzheimer's disease
2. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease
3. What are the facts and artifacts of the pathogenesis and etiology of Alzheimer disease?
4. Amyloid beta-peptide is produced by cultured cells during normal metabolism
5. Molecular and cellular aspects of oxidative damage in Alzheimer's disease
6. Oxidative stress in Alzheimer's disease
7. Mitochondrial involvement in Alzheimer's disease
8. Oxidative damage and mitochondrial decay in aging
9. Is oxidative damage the common mechanism of neurodegenerative diseases?
10. Metals and neuroscience
11. Copper catalyzed oxidation of ascorbate (vitamin C). Inhibitory effect of catalase, superoxide dismutase, serum proteins (ceruloplasmin, albumin, apotransferrin) and amino acids
12. Antiinflammatory activity of methionine, methionine sulfoxide and methionine sulfone
13. Tl2+ and Ag2+ metal-ion-induced oxidation of methionine in aqueous solution. A pulse radiolysis study
14. Characterization of copper interactions with Alzheimer amyloid beta peptides: Identification of an attomolar-affinity copper binding site on amyloid beta1-42
15. Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes
16. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits
17. The Abeta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction
18. Cu(II) potentiation of Alzheimer Abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction
19. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging
20. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII
21. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease
22. Mitochondrial free radical generation, oxidative stress, and aging
23. Amyloid beta peptides do not form peptide-derived free radicals spontaneously, but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides
24. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity
25. Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma
26. Hydrogen peroxide mediates amyloid beta protein toxicity
27. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide
28. Amyloid-beta peptides are cytotoxic to oligodendrocytes
29. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: Involvement of membrane lipid peroxidation
30. Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease
31. Oxidative stress hypothesis in Alzheimer's disease
32. The toxicity in vitro of beta-amyloid protein
33. Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations
34. Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis
35. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease
36. Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid
37. The role of iron in beta amyloid toxicity
38. Redox-active iron mediates amyloid-beta toxicity
39. Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions
40. The effect of albumin on copper-induced LDL oxidation
41. Lipoprotein oxidation: Mechanistic aspects, methodological approaches and clinical relevance
42. Alpha-tocopherol as a reductant for Cu(II) in human lipoproteins
43. Antioxidant and pro-oxidant activity of alpha-tocopherol in human plasma and low density lipoprotein
44. Resistance of human cerebrospinal fluid to in vitro oxidation is directly related to its amyloid-beta content
45. The effect of ascorbate and ubiquinone supplementation on plasma and CSF total antioxidant capacity
46. Increased lipoprotein oxidation in Alzheimer's disease
47. Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls
48. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
49. RNA oxidation in Alzheimer and Parkinson diseases
50. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome
51. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells
52. Platelets are the primary source of amyloid beta-peptide in human blood
53. Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation
54. Intracellular and secreted Alzheimer beta-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons
55. Alzheimer's soluble amyloid beta protein is secreted by HepG2 cells as an apolipoprotein
56. Distribution and fluidizing action of soluble and aggregated amyloid beta-peptide in rat synaptic plasma membranes
57. Peptides in membranes: Tipping the balance of membrane stability
58. Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: Association with high density lipoproteins
59. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma
60. Neuronal cell cultures protect low density lipoprotein from oxidation
61. Ambivalent effect of protein binding on computed distributions of metal ions complexed by ligands in blood plasma
62. Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase
63. Beta-amyloid protein promotes neuritic branching in hippocampal cultures
64. Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides
65. Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth
66. Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells
67. 2-induced apoptosis in human neuronal cells
68. N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: Effects on beta-amyloid secretion and tau phosphorylation
69. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells
70. Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells
71. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide
72. Increased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: Possible involvement of apoptosis
73. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative
74. Traumatic brain injury increases beta-amyloid peptide 1-42 in cerebrospinal fluid
75. A beta 42 is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury
76. Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain
77. Does human betaA4 exert a protective function against oxidative stress in Alzheimer's disease?
78. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease
79. Amyloid beta protein enhances the survival of hippocampal neurons in vitro
80. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans
81. Differential alterations in antioxidant capacity in cells from Alzheimer patients
82. Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer disease mutant does not enhance apoptosis
83. Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations
84. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis
85. Brain alpha-ketoglutarate dehydrogenase complex: Kinetic properties, regional distribution, and effects of inhibitors
86. Differential expression of cytochrome oxidase (COX) genes in different regions of monkey brain
87. Normal and pathological aging: Findings of positron-emission-tomography
88. Reactive oxygen species mediate cellular damage in Alzheimer's disease
89. Rapid induction of Alzheimer A beta amyloid formation by zinc
90. Is copper pro- or anti-inflammatory? A reconciling view and a novel approach for the use of copper in the control of inflammation
91. Microglial in neurodegenerative disorders: Emphasis on Alzheimer's disease
92. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders
93. The oxidation of lipoproteins by monocytes-macrophages. Biochemical and biological mechanisms
94. Nerve endings from rat brain tissue release copper upon depolarization. A possible role in regulating neuronal excitability
95. Lipoproteins in the brain: A new frontier?
96. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition
97. Copper, iron and zinc in Alzheimer's disease senile plaques
98. Mechanisms of neuronal degeneration in Alzheimer's disease
99. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse
100. Targeting small Abeta oligomers: The solution to an Alzheimer's disease conundrum?
101. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Abeta by zinc
102. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome
103. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: A central role for bound transition metals
104. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
105. Arson. Tracking the culprit in Alzheimer's disease
106. Aluminium and Alzheimer's disease
107. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide
108. Apolipoprotein E4: An allele associated with many diseases
109. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides
110. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion
111. Intramuscular desferrioxamine in patients with Alzheimer's disease
112. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice
113. Statins and the risk of dementia
114. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
115. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons
116. The role of cholesterol in the biosynthesis of beta-amyloid
117. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid
118. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls
119. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid
120. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol
121. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model
122. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
123. Influence of supplementation with vitamin E and C on lipoprotein oxidation in patients with Alzheimer's disease
124. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease